108 related articles for article (PubMed ID: 32174016)
1. Is prospective MRI mapping of the changes in the volume of the prostate gland in prostate cancer patients undergoing 6 months of neo-adjuvant androgen deprivation therapy a step towards a trial to determine those who may benefit from treatment intensification or extended duration?
Christie DR; Sharpley CF; Mitina N; MacAteer E; Jackson JE; Lunn D
J Med Imaging Radiat Oncol; 2020 Apr; 64(2):287-292. PubMed ID: 32174016
[TBL] [Abstract][Full Text] [Related]
2. A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer.
Miki K; Sasaki H; Kido M; Takahashi H; Aoki M; Egawa S
BMC Cancer; 2016 Sep; 16(1):708. PubMed ID: 27586506
[TBL] [Abstract][Full Text] [Related]
3. Antivascular effects of neoadjuvant androgen deprivation for prostate cancer: an in vivo human study using susceptibility and relaxivity dynamic MRI.
Alonzi R; Padhani AR; Taylor NJ; Collins DJ; D'Arcy JA; Stirling JJ; Saunders MI; Hoskin PJ
Int J Radiat Oncol Biol Phys; 2011 Jul; 80(3):721-7. PubMed ID: 20630668
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant androgen deprivation and prostate gland shrinkage during conformal radiotherapy.
Sanguineti G; Marcenaro M; Franzone P; Foppiano F; Vitale V
Radiother Oncol; 2003 Feb; 66(2):151-7. PubMed ID: 12648786
[TBL] [Abstract][Full Text] [Related]
5. Higher percentage of positive biopsy cores and Gleason score are associated with a greater degree of prostate gland shrinkage after neoadjuvant cytoreductive therapy.
Bittner N; Merrick GS; Butler WM; Galbreath RW; Anderson RL; Adamovich E; Wallner KE
Brachytherapy; 2012; 11(3):219-23. PubMed ID: 21820364
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant versus neoadjuvant androgen deprivation with radiotherapy for prostate cancer: does sequencing matter?
Weller MA; Kupelian PA; Reddy CA; Stephans KL; Tendulkar RD
Clin Genitourin Cancer; 2015 Jun; 13(3):e183-9. PubMed ID: 25660127
[TBL] [Abstract][Full Text] [Related]
7. Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity after permanent interstitial brachytherapy.
Hinerman-Mulroy A; Merrick GS; Butler WM; Wallner KE; Allen Z; Adamovich E
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1367-82. PubMed ID: 15275722
[TBL] [Abstract][Full Text] [Related]
8. Prostate volume reduction with androgen deprivation therapy before interstitial brachytherapy.
Kucway R; Vicini F; Huang R; Stromberg J; Gonzalez J; Martinez A
J Urol; 2002 Jun; 167(6):2443-7. PubMed ID: 11992054
[TBL] [Abstract][Full Text] [Related]
9. Factors Predicting the Off-treatment Duration in Patients with Prostate Cancer Receiving Degarelix as Intermittent Androgen Deprivation Therapy.
Abrahamsson PA; Boccon-Gibod L; Morote J; de Jong IJ; Malmberg A; Neijber A; Albers P
Eur Urol Focus; 2017 Oct; 3(4-5):470-479. PubMed ID: 28753747
[TBL] [Abstract][Full Text] [Related]
10. Fate of seminal vesicles and prostate after medical castration: how long is the optimal duration of neoadjuvant treatment for prostate cancer before radiation?
Furuya R; Hisasue S; Furuya S; Saitoh N; Ogura H; Takahashi S; Tsukamoto T
Urology; 2008 Aug; 72(2):417-21. PubMed ID: 18267337
[TBL] [Abstract][Full Text] [Related]
11. Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer.
Gleave ME; Goldenberg SL; Jones EC; Bruchovsky N; Sullivan LD
J Urol; 1996 Jan; 155(1):213-9. PubMed ID: 7490838
[TBL] [Abstract][Full Text] [Related]
12. Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide.
Axcrona K; Aaltomaa S; da Silva CM; Ozen H; Damber JE; Tankó LB; Colli E; Klarskov P
BJU Int; 2012 Dec; 110(11):1721-8. PubMed ID: 22500884
[TBL] [Abstract][Full Text] [Related]
13. Salvage of locally recurrent prostate cancer after external beam radiation using reduced-dose brachytherapy with neoadjuvant plus adjuvant androgen deprivation.
Baumann BC; Baumann JC; Christodouleas JP; Soffen E
Brachytherapy; 2017; 16(2):291-298. PubMed ID: 28139422
[TBL] [Abstract][Full Text] [Related]
14. Effects of androgen deprivation on prostatic morphology and vascular permeability evaluated with mr imaging.
Padhani AR; MacVicar AD; Gapinski CJ; Dearnaley DP; Parker GJ; Suckling J; Leach MO; Husband JE
Radiology; 2001 Feb; 218(2):365-74. PubMed ID: 11161148
[TBL] [Abstract][Full Text] [Related]
15. Acceptability of short term neo-adjuvant androgen deprivation in patients with locally advanced prostate cancer.
Lamb DS; Denham JW; Mameghan H; Joseph D; Turner S; Matthews J; Franklin I; Atkinson C; North J; Poulsen M; Kovacev O; Robertson R; Francis L; Christie D; Spry NA; Tai KH; Wynne C; Duchesne G
Radiother Oncol; 2003 Sep; 68(3):255-67. PubMed ID: 13129633
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of neoadjuvant androgen deprivation followed by external-beam radiotherapy with 9 months of androgen deprivation for intermediate- to high-risk localized prostate cancer.
Heymann JJ; Benson MC; O'Toole KM; Malyszko B; Brody R; Vecchio D; Schiff PB; Mansukhani MM; Ennis RD
J Clin Oncol; 2007 Jan; 25(1):77-84. PubMed ID: 17194907
[TBL] [Abstract][Full Text] [Related]
17. Computed tomography/magnetic resonance based volume changes of the primary tumour in patients with prostate cancer with or without androgen deprivation.
Lilleby W; Fosså SD; Knutsen BH; Abildgaard A; Skovlund E; Lien HH
Radiother Oncol; 2000 Nov; 57(2):195-200. PubMed ID: 11054523
[TBL] [Abstract][Full Text] [Related]
18. Biochemical response to androgen deprivation therapy before external beam radiation therapy predicts long-term prostate cancer survival outcomes.
Zelefsky MJ; Gomez DR; Polkinghorn WR; Pei X; Kollmeier M
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):529-33. PubMed ID: 23523323
[TBL] [Abstract][Full Text] [Related]
19. Assessment of prostate cancer volume using endorectal coil magnetic resonance imaging: a new predictor of tumor response to neoadjuvant androgen suppression therapy.
D'Amico AV; Chang E; Garnick M; Kantoff P; Jiroutek M; Tempany CM
Urology; 1998 Feb; 51(2):287-92. PubMed ID: 9495713
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen halving time while on neoadjuvant androgen deprivation therapy is associated with biochemical control in men treated with radiation therapy for localized prostate cancer.
Malik R; Jani AB; Liauw SL
Int J Radiat Oncol Biol Phys; 2011 Mar; 79(4):1022-8. PubMed ID: 20510547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
